drugset / Trial / NCT00244543

Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

NCT00244543

Phase 3 Completed 110 enrolled Vistakon Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis

Timeline

Start
2005-10
Primary completion
2005-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Alcaftadine Small molecule 0.25 % Other

Indications